Riskpilot← Back to searchSign inGet full accessSOLAMED AS
ASActiveOrg 913853334Framnesveien 7, 4632 Kristiansand SGeneral medical practice activities · NACE 8621Est. 20141 employees
Revenue 2024
NOK 3,3M
+3% vs 2023
EBITDA margin
33.7%
-22% vs 2023
Equity ratio
92.6%
Financial strength
Net profit 2024
NOK 843K
-19% vs 2023
| Revenue | NOK 3,3M | +3% |
| EBITDA | NOK 1,1M | -22% |
| Net profit | NOK 843K | -19% |
| Total assets | NOK 7,4M | +9% |
| Equity | NOK 6,9M | +10% |
| Employees | 1 | — |
Legal name
SOLAMED AS
Org number
913853334
Legal form
Aksjeselskap
NACE code
8621 · General medical practice activities
Founded
4. juli 2014
Share capital
NOK 60 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Helsevirksomhet med utgangspunkt i legearbeid, deriblant allmennlegekontor, spesialistpraksis for fysikalsk medisin, idrettslegearbeid og annet som står i forbindelse med dette, deriblant tverrfaglige arbeid og arrangementer. Selskapet kan og foreta investeringer i aksjer og fast eiendom.
Address
Framnesveien 7, 4632 Kristiansand S
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 702 | 3 037 | 3 057 | 3 228 | 3 331 |
| Staff expenses | −737 | −987 | −981 | −1 057 | −1 122 |
| EBITDA | 1 320 | 1 013 | 1 231 | 1 438 | 1 121 |
| Depreciation & amort. | −66 | −21 | −149 | −149 | −79 |
| EBIT | 1 254 | 991 | 1 082 | 1 289 | 1 042 |
| Net financials | 10 | 104 | −90 | 42 | 85 |
| Profit before tax | 1 264 | 1 096 | 992 | 1 331 | 1 127 |
| Tax | 279 | 242 | 240 | 293 | 284 |
| Net profit | 985 | 854 | 752 | 1 038 | 843 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 254 | 4 762 | 5 456 | 6 790 | 7 425 |
| Equity | 3 841 | 4 245 | 4 997 | 6 235 | 6 878 |
| Long-term debt | 12 | 8 | 4 | 0 | 105 |
| Short-term debt | 401 | 509 | 455 | 555 | 442 |
| Total debt | 413 | 517 | 459 | 555 | 547 |
EBITDA margin
33.7%
This company
15.8%
Market median
+113% vs market
20202024
Equity ratio
92.6%
This company
38.2%
Market median
+142% vs market
20202024
Return on equity
12.3%
This company
18.4%
Market median
+33% vs market
20202024
Net profit margin
25.3%
This company
8.1%
Market median
+212% vs market
20202024
Asset turnover
0.45×
This company
1.12×
Market median
-60% vs market
20202024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KS Chief Executive Officer | Chief Executive Officer | 2014 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SOLAMED AS 
GIMLE LEGESENTER ASBoard members of SOLAMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kirsten Sola | Chief Executive Officer | 0 companies |